Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2025-12-23 00:00:00 ET · period of report 2025-12-22 · accession 0001882764-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-23 | 2025-12-22 | ELVN | Hohl Benjamin | CFO | M - OptEx | $2.48 | +13.0K | 36.0K | +57% | +$32.2K |
| D | 2025-12-23 | 2025-12-22 | ELVN | Hohl Benjamin | CFO | M - OptEx | $0.00 | -13.0K | 92.1K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-22 | M | A | 13,000 | $2.48 | 36,000 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2025-12-22 | M | D | 13,000 | $0.00 | 92,056 | D | $2.48 · — to 2031-08-02 | 13,000 Common Stock | (F1) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |